PreClinical Services

SNBL USA is committed to providing clients with quality you expect with your preclinical needs. We are committed to providing service you trust with the turnaround you need.

Nucleic Acid Therapeutics

As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.

Laboratory Services

Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.


Go Hawks!

Posted on Jan 21, 2015

Go Hawks!

Congratulations to our own Seattle Seahawks for a spectacular win in Sunday’s NFC Playoff game! We’re headed to the Super Bowl for the second year in a row – another unbelievable accomplishment!  See you in Arizona on Sunday, February 1st. Go Hawks!

Read More

Cambridge Health Institute PepTalk, Dr. Michael Templin Presenting

Posted on Jan 9, 2015

Cambridge Health Institute PepTalk, Dr. Michael Templin Presenting

PepTalk, hosted by Cambridge Health Institute, provides access to cutting-edge research in protein expression and analysis, and brings together many academic and industrial scientists, who have a very broad prospective on all the key subjects in the field. SNBL USA’s own, Dr. Michael Templin, Technical Director, is scheduled to present on January 23 @ 12:30 PM within the ‘Bispecific Antibody Therapeutics’ pipeline track. For more information, visit this page and scroll down to the 12:30 PM presentation: “After the Development Candidate has been selected: Successful...

Read More

PPD and SNBL Announce Japanese Clinical Development Joint Venture and Additional Collaborations

Posted on Dec 30, 2014

PPD and SNBL Announce Japanese Clinical Development Joint Venture and Additional Collaborations

WILMINGTON, N.C., and TOKYO (December 24, 2014) – Pharmaceutical Product Development, LLC (PPD) and Shin Nippon Biomedical Laboratories Ltd. (SNBL) (TSE:2395) today announced an agreement to form a joint venture that will provide a full range of clinical development services in Japan, including Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services. The joint venture, to be named PPD-SNBL, will result from the combination of SNBL’s clinical research division...

Read More